Nuveen Asset Management’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $4.66M | Buy |
495,727
+48,635
| +11% | +$458K | ﹤0.01% | 2015 |
|
|
2024
Q3 | $3.6M | Buy |
447,092
+104,377
| +30% | +$841K | ﹤0.01% | 2138 |
|
|
2024
Q2 | $2.91M | Buy |
342,715
+182,897
| +114% | +$1.55M | ﹤0.01% | 2201 |
|
|
2024
Q1 | $1.43M | Hold |
159,818
| – | – | ﹤0.01% | 2551 |
|
|
2023
Q4 | $1.8M | Sell |
159,818
-4,770
| -3% | -$53.6K | ﹤0.01% | 2459 |
|
|
2023
Q3 | $1.42M | Buy |
164,588
+7,259
| +5% | +$62.6K | ﹤0.01% | 2433 |
|
|
2023
Q2 | $1.63M | Buy |
157,329
+2,819
| +2% | +$29.2K | ﹤0.01% | 2432 |
|
|
2023
Q1 | $1.68M | Sell |
154,510
-97,537
| -39% | -$1.06M | ﹤0.01% | 2409 |
|
|
2022
Q4 | $2.83M | Buy |
252,047
+75,874
| +43% | +$851K | ﹤0.01% | 2229 |
|
|
2022
Q3 | $1.79M | Sell |
176,173
-63,989
| -27% | -$649K | ﹤0.01% | 2454 |
|
|
2022
Q2 | $2.18M | Buy |
240,162
+53,256
| +28% | +$483K | ﹤0.01% | 2399 |
|
|
2022
Q1 | $1.81M | Buy |
186,906
+22,116
| +13% | +$214K | ﹤0.01% | 2546 |
|
|
2021
Q4 | $1.65M | Sell |
164,790
-11,927
| -7% | -$119K | ﹤0.01% | 2658 |
|
|
2021
Q3 | $1.26M | Sell |
176,717
-10,955
| -6% | -$77.9K | ﹤0.01% | 2897 |
|
|
2021
Q2 | $2.73M | Sell |
187,672
-4,215
| -2% | -$61.2K | ﹤0.01% | 2561 |
|
|
2021
Q1 | $3.92M | Buy |
191,887
+1,727
| +0.9% | +$35.2K | ﹤0.01% | 2287 |
|
|
2020
Q4 | $3.38M | Sell |
190,160
-19,473
| -9% | -$346K | ﹤0.01% | 2256 |
|
|
2020
Q3 | $3.1M | Sell |
209,633
-6,020
| -3% | -$89K | ﹤0.01% | 2162 |
|
|
2020
Q2 | $4.53M | Sell |
215,653
-86,492
| -29% | -$1.82M | ﹤0.01% | 1952 |
|
|
2020
Q1 | $6.98M | Buy |
302,145
+30,194
| +11% | +$698K | ﹤0.01% | 1515 |
|
|
2019
Q4 | $7.04M | Sell |
271,951
-5,840
| -2% | -$151K | ﹤0.01% | 1804 |
|
|
2019
Q3 | $5.41M | Buy |
277,791
+56,699
| +26% | +$1.1M | ﹤0.01% | 1912 |
|
|
2019
Q2 | $3.61M | Buy |
+221,092
| New | +$3.61M | ﹤0.01% | 2161 |
|